Cytek Overview

  • Year Founded
  • 1992

Year Founded

  • Status
  • Public

  • Employees
  • 645

Employees

  • Stock Symbol
  • CTKB

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $5.23
  • (As of Friday Closing)

Cytek General Information

Description

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 47215 Lakeview Boulevard
  • Fremont, CA 94538-6407
  • United States
+1 (877)
Primary Industry
Other Devices and Supplies
Other Industries
Biotechnology
Other Healthcare Technology Systems
Stock Exchange
NAS
Corporate Office
  • 47215 Lakeview Boulevard
  • Fremont, CA 94538-6407
  • United States
+1 (877)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytek Stock Performance

As of 14-Feb-2025, Cytek’s stock price is $5.23. Its current market cap is $674M with 129M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.23 $5.22 $4.66 - $9.33 $674M 129M 708K -$0.08

Cytek Financials Summary

As of 30-Sep-2024, Cytek has a trailing 12-month revenue of $201M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 465,106 963,489 1,051,131 1,805,951
Revenue 201,210 193,015 164,036 127,950
EBITDA (6,306) (10,821) 4,873 8,872
Net Income (10,160) (12,148) 2,576 3,001
Total Assets 491,226 494,457 519,476 463,305
Total Debt 14,518 14,136 18,094 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cytek Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cytek‘s full profile, request access.

Request a free trial

Cytek Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Cytek‘s full profile, request access.

Request a free trial

Cytek Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by lever
Other Devices and Supplies
Fremont, CA
645 As of 2024

Gurugram, India
 

Broomfield, CO
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cytek Competitors (4)

One of Cytek’s 4 competitors is Imperial Life Sciences, a Corporation company based in Gurugram, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Imperial Life Sciences Corporation Gurugram, India
FluoroFinder Venture Capital-Backed Broomfield, CO
Active Motif Private Equity-Backed Carlsbad, CA
Treefrog Therapeutics Venture Capital-Backed Pessac, France
To view Cytek’s complete competitors history, request access »

Cytek Patents

Cytek Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250020639-A1 Ultra-bright nanoparticle fluorescent dye complexes Pending 18-Jun-2023
US-20240210397-A1 High parameter flow cytometric assay to identify human myeloid derived suppressive cells Pending 14-Dec-2022
US-20240159757-A1 High parameter 20 color panel for effective detection of aberrant cells in acute myeloid leukemia Pending 20-Oct-2022
US-20240226872-A9 Removable circular nozzle for flow cytometers Pending 20-Oct-2022
US-20240131506-A1 Removable circular nozzle for flow cytometers Pending 20-Oct-2022 B01L3/502
To view Cytek’s complete patent history, request access »

Cytek Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cytek Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cytek‘s full profile, request access.

Request a free trial

Cytek Acquisitions (4)

Cytek’s most recent deal was a Merger/Acquisition with Luminex (Flow Cytometry & Imaging Business) for . The deal was made on 28-Feb-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Luminex (Flow Cytometry & Imaging Business) 28-Feb-2023 Merger/Acquisition Biotechnology
Merck (Flow Cytometry Unit) 28-Feb-2023 Merger/Acquisition Pharmaceuticals
Tonbo Biosciences 02-Nov-2021 Merger/Acquisition Biotechnology
Cytoville Merger of Equals Other Devices and Supplies
To view Cytek’s complete acquisitions history, request access »

Cytek ESG

Risk Overview

Risk Rating

Updated June, 07, 2023

29.05 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Healthcare

Industry

of 587

Rank

Percentile

Medical Devices

Subindustry

of 199

Rank

Percentile

To view Cytek’s complete esg history, request access »

Cytek FAQs

  • When was Cytek founded?

    Cytek was founded in 1992.

  • Where is Cytek headquartered?

    Cytek is headquartered in Fremont, CA.

  • What is the size of Cytek?

    Cytek has 645 total employees.

  • What industry is Cytek in?

    Cytek’s primary industry is Other Devices and Supplies.

  • Is Cytek a private or public company?

    Cytek is a Public company.

  • What is Cytek’s stock symbol?

    The ticker symbol for Cytek is CTKB.

  • What is the current stock price of Cytek?

    As of 14-Feb-2025 the stock price of Cytek is $5.23.

  • What is the current market cap of Cytek?

    The current market capitalization of Cytek is $674M.

  • What is Cytek’s current revenue?

    The trailing twelve month revenue for Cytek is $201M.

  • Who are Cytek’s competitors?

    Imperial Life Sciences, FluoroFinder, Active Motif, and Treefrog Therapeutics are competitors of Cytek.

  • What is Cytek’s annual earnings per share (EPS)?

    Cytek’s EPS for 12 months was -$0.08.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »